Compare 3M Company (MMM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs TG Therapeutics Inc — how do they compare? 3M Company trades at $170.77 (market cap $82.99B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: 3M Company is far larger — about 10× TG Therapeutics Inc's market cap, and 3M Company pays a 1.96% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MMM | TGTX | |
|---|---|---|
Market Cap | $82.99B | $8.26B |
Sector | Industrials | Health |
52-Week High | $174.61 | $59.06 |
52-Week Low | $141.10 | $26.39 |
Enterprise Value | $91.39B | $8.50B |
Dividend Yield | 1.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
3M (MMM) surged 6.83% to $170.76 following strong Q2 2026 earnings that beat expectations, with the company raising full-year guidance. Technical indicators show a bullish trend with support at $158 and resistance at $161. Fundamentally, the company demonstrates robust profitability with 39.71% gross margins and 72.14% ROE, though revenue has declined from 2022 peaks. Recent news highlights operational improvements and growth in Safety & Industrial and Transport & Electronics segments.
The outlook is positive with earnings momentum and raised guidance, but risks include litigation liabilities and macroeconomic headwinds. Analyst consensus is mixed with 48% buy ratings but a $149.75 price target below current levels, suggesting limited near-term upside despite strong operational performance.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
